Literature DB >> 30942139

FSH therapy for idiopathic male infertility: four schemes are better than one.

Sandro La Vignera1, Rosita A Condorelli1, Ylenia Duca1, Laura M Mongioi1, Rossella Cannarella1, Filippo Giacone1, Aldo E Calogero1.   

Abstract

OBJECTIVE: The aim of this article is to propose an algorithm that aids the clinician to choose the best therapeutic scheme of follicle-stimulating hormone (FSH) in the treatment of men with idiopathic infertility, based on testicular volume (TV) and serum total testosterone concentrations; highlighting the potential role of additional therapy with hCG in a sequential temporal scheme.
MATERIALS AND METHODS: We subdivided patients in four clinical groups: patients with normal TV and serum testosterone concentrations (A); patients with normal TV and reduced serum testosterone concentrations (B); patients with reduced TV and serum testosterone concentration (C); patient with low TV e normal serum testosterone concentrations (D). Then, we administered to each group a specific therapeutic scheme. Group A: treated with FSH alone for at least 3 months; group B: treated with hCG alone twice a week for 3 months and addition of FSH for poor responders (unmodified sperm parameters); group C: treated ab initio with FSH and hCG until the pregnancy was reached; group D: treated with FSH alone for 3 months and addition of hCG for moderate poor responders (increased TV but unmodified sperm parameters) or second cycle of FSH for 3 months for severe poor responders (unmodified TV and sperm parameters). After 6 months we evaluated the therapeutic response in term of sperm parameters normalization rate, spontaneous pregnancy rate, and sperm DNA fragmentation normalization rate.
RESULTS: 40% of patients became normozoospermic after treatment, while 30% achieved spontaneous pregnancy. B was the group that best responded to treatment in terms of normalization of seminal parameters; while the highest spontaneous pregnancy rate was obtained from the D group. B group also obtained the highest sperm DNA fragmentation normalization rate.
CONCLUSIONS: To date, no reliable predictors of response to treatment with FSH exist, but TV and serum testosterone concentrations can help the clinician to choose the best therapeutic scheme for men with idiopathic infertility. The groups treated with a sequential temporal scheme (B and D groups) showed better clinical results compared with two groups treated with conventional schemes (A and C groups).

Entities:  

Keywords:  Follicle-stimulating hormone (FSH); azoospermia; empiric therapy; idiopathic male infertility; oligoasthenoteratozoospermia (OAT)

Mesh:

Substances:

Year:  2019        PMID: 30942139     DOI: 10.1080/13685538.2019.1590696

Source DB:  PubMed          Journal:  Aging Male        ISSN: 1368-5538            Impact factor:   5.892


  4 in total

1.  Testosterone levels after treatment with urofollitropin in infertile patients with idiopathic mild reduction of testicular volume.

Authors:  Sandro La Vignera; Rosita A Condorelli; Rossella Cannarella; Laura Cimino; Laura Mongioi'; Ylenia Duca; Filippo Giacone; Aldo E Calogero
Journal:  Endocrine       Date:  2019-06-25       Impact factor: 3.633

2.  Automated-Mechanical Procedure Compared to Gentle Enzymatic Tissue Dissociation in Cell Function Studies.

Authors:  Mariele Montanari; Sabrina Burattini; Caterina Ciacci; Patrizia Ambrogini; Silvia Carloni; Walter Balduini; Daniele Lopez; Giovanna Panza; Stefano Papa; Barbara Canonico
Journal:  Biomolecules       Date:  2022-05-14

3.  Early Identification of Isolated Sertoli Cell Dysfunction in Prepubertal and Transition Age: Is It Time?

Authors:  Sandro La Vignera; Rosita A Condorelli; Laura Cimino; Rossella Cannarella; Filippo Giacone; Aldo E Calogero
Journal:  J Clin Med       Date:  2019-05-09       Impact factor: 4.241

Review 4.  Evaluation of Sperm Mitochondrial Function: A Key Organelle for Sperm Motility.

Authors:  Federica Barbagallo; Sandro La Vignera; Rossella Cannarella; Antonio Aversa; Aldo E Calogero; Rosita A Condorelli
Journal:  J Clin Med       Date:  2020-01-29       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.